Literature DB >> 28941088

Advances and challenges in early intervention in psychosis.

Ashok Malla1, Jai Shah1,2, Shalini Lal3.   

Abstract

Entities:  

Year:  2017        PMID： 28941088      PMCID： PMC5608857          DOI： 10.1002/wps.20453

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  10 in total

1.  Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years.

Authors:  Clifford M Cassidy; Ross Norman; Rahul Manchanda; Norbert Schmitz; Ashok Malla
Journal:  Schizophr Bull       Date:  2009-03-25       Impact factor: 9.306

Review 2.  Psychological and psychosocial interventions for negative symptoms in psychosis: systematic review and meta-analysis.

Authors:  Danyael Lutgens; Genevieve Gariepy; Ashok Malla
Journal:  Br J Psychiatry       Date:  2017-03-16       Impact factor: 9.319

3.  Can we identify and treat "schizophrenia light" to prevent true psychotic illness?

Authors:  Jim van Os; Robin M Murray
Journal:  BMJ       Date:  2013-01-18

4.  Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value.

Authors:  Jan Scott; Marion Leboyer; Ian Hickie; Michael Berk; Flavio Kapczinski; Ellen Frank; David Kupfer; Patrick McGorry
Journal:  Br J Psychiatry       Date:  2013-04       Impact factor: 9.319

5.  The Bidirectional Associations Between Psychotic Experiences and DSM-IV Mental Disorders.

Authors:  John J McGrath; Sukanta Saha; Ali Al-Hamzawi; Laura Andrade; Corina Benjet; Evelyn J Bromet; Mark Oakley Browne; Jose M Caldas de Almeida; Wai Tat Chiu; Koen Demyttenaere; John Fayyad; Silvia Florescu; Giovanni de Girolamo; Oye Gureje; Josep Maria Haro; Margreet Ten Have; Chiyi Hu; Viviane Kovess-Masfety; Carmen C W Lim; Fernando Navarro-Mateu; Nancy Sampson; José Posada-Villa; Kenneth S Kendler; Ronald C Kessler
Journal:  Am J Psychiatry       Date:  2016-03-17       Impact factor: 18.112

6.  EPA guidance on the early detection of clinical high risk states of psychoses.

Authors:  F Schultze-Lutter; C Michel; S J Schmidt; B G Schimmelmann; N P Maric; R K R Salokangas; A Riecher-Rössler; M van der Gaag; M Nordentoft; A Raballo; A Meneghelli; M Marshall; A Morrison; S Ruhrmann; J Klosterkötter
Journal:  Eur Psychiatry       Date:  2015-02-27       Impact factor: 5.361

Review 7.  Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders.

Authors:  Molly K Larson; Elaine F Walker; Michael T Compton
Journal:  Expert Rev Neurother       Date:  2010-08       Impact factor: 4.618

Review 8.  Remission in schizophrenia: proposed criteria and rationale for consensus.

Authors:  Nancy C Andreasen; William T Carpenter; John M Kane; Robert A Lasser; Stephen R Marder; Daniel R Weinberger
Journal:  Am J Psychiatry       Date:  2005-03       Impact factor: 18.112

9.  The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis.

Authors:  Gerald Jordan; Danyael Lutgens; Ridha Joober; Martin Lepage; Srividya N Iyer; Ashok Malla
Journal:  J Clin Psychiatry       Date:  2014-06       Impact factor: 4.384

10.  Specificity of childhood psychotic symptoms for predicting schizophrenia by 38 years of age: a birth cohort study.

Authors:  H L Fisher; A Caspi; R Poulton; M H Meier; R Houts; H Harrington; L Arseneault; T E Moffitt
Journal:  Psychol Med       Date:  2013-01-10       Impact factor: 7.723
  10 in total
  2 in total

1.  The complexity of vulnerability to psychosis.

Authors:  Andrea Fiorillo
Journal:  Epidemiol Psychiatr Sci       Date:  2018-11-29       Impact factor: 6.892

2.  Familiarity for Serious Mental Illness in Help-Seeking Adolescents at Clinical High Risk of Psychosis.

Authors:  Michele Poletti; Silvia Azzali; Federica Paterlini; Sara Garlassi; Ilaria Scazza; Luigi Rocco Chiri; Simona Pupo; Andrea Raballo; Lorenzo Pelizza
Journal:  Front Psychiatry       Date:  2021-01-08       Impact factor: 4.157
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.